Ex-pharmaceutical executive Martin Shkreli and his former outside counsel, Evan Greebel, are anxious to part ways as co-defendants as they point fingers at one another. But federal prosecutors in Brooklyn said the fraud charges they face are “inextricably intertwined” and are urging a judge to keep their trial joined.
Shkreli faces eight counts for allegedly scheming to defraud investors in two hedge funds he founded and then scheming to misappropriate assets from the biopharmaceutical company he chaired, Retrophin, to pay off the defrauded hedge fund investors. Greebel, indicted with Shkreli in December 2015, is charged in two of the eight counts, both related to the Retrophin scheme.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
